Related Experiment Videos
Interval debulking surgery: an alternative for primary surgical debulking?
I Vergote1, I de Wever, W Tjalma
1Department of Gynaecological Oncology University Hospital, Leuven, Belgium. Ignace.Vergote@uz.kuleuven.ac.be
Seminars in Surgical Oncology
|July 7, 2000
Summary
Neoadjuvant chemotherapy followed by interval debulking surgery may benefit select ovarian cancer patients. Further prospective trials are needed to confirm its efficacy in improving survival outcomes.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Retrospective analyses indicate potential benefits of neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) for Stage III-IV ovarian carcinoma.
- Specific indications for NAC are emerging, including Stage IV disease and unresectable metastases.
Purpose of the Study:
- To review existing studies on NAC and IDS in ovarian cancer.
- To discuss indications for NAC prior to IDS.
- To highlight ongoing trials investigating this treatment strategy.
Main Methods:
- Review of retrospective analyses and prospective randomized trials.
- Analysis of indications for neoadjuvant chemotherapy.
- Discussion of European Organization for Research and Treatment of Cancer (EORTC) trials.
Main Results:
- NAC followed by IDS shows promise for a subgroup of ovarian cancer patients.
- Absolute indications include Stage IV disease or unresectable metastases >1g.
- Relative indications for high tumor burden include peritoneal metastases, ascites, and poor WHO performance status.
Conclusions:
- NAC followed by IDS may improve survival in select ovarian cancer patients.
- The strategy requires confirmation in prospective randomized trials.
- The EORTC 55971 trial is actively investigating this approach.